CSTL on Nasdaq
CASTLE BIOSCIENCES INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Fulgent Genetics, CareDx, Inc or BillionToOne (United States), or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-12.4%Operating margin3
-7.0%Net margin3
3.7%Revenue growth, 20253
-5.1%Return on equity3
0.02×Debt to equity3
$28.3MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Dermatologic brought in 63% of the revenue CASTLE BIOSCIENCES INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Dermatologic | $183.4M | $257.0M | $216.4M |
| Non-Dermatologic | $36.4M | $75.1M | $127.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue20¢$71.0M
- Research and development15¢$51.9M
- Selling, general and admin64¢$229.3M
- Income tax1¢$5.4M
Out of $344.2M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending56¢$36.0M
- Kept or used elsewhere44¢$28.3M
Out of $64.3M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| NET REVENUES | $344.2M | $332.1M | $219.8M |
| Cost of sales (exclusive of amortization of acquired intangible assets) | $71.0M | $60.2M | $45.0M |
| Research and development | $51.9M | $52.0M | $53.6M |
| Selling, general and administrative | $229.3M | $200.0M | $180.2M |
| Amortization of acquired intangible assets | $34.8M | $11.1M | $9.0M |
| Total operating expenses, net | $387.0M | $323.4M | $287.8M |
| Operating (loss) income | -$42.8M | $8.7M | -$68.0M |
| Interest income | $11.8M | $12.9M | $10.6M |
| Net gains on equity securities | $1.5M | $555.0K | $0 |
| Interest expense | -$86.0K | -$577.0K | -$11.0K |
| Other income | $144.0K | $0 | $0 |
| (Loss) income before income taxes | -$29.5M | $21.6M | -$57.4M |
| Income tax (benefit) expense | -$5.4M | $3.3M | $101.0K |
| Net (loss) income | -$24.2M | $18.2M | -$57.5M |
| Basic (in dollars per share) | -$0.83 | $0.66 | -$2.14 |
| Diluted (in dollars per share) | -$0.83 | $0.62 | -$2.14 |
| Basic (in shares) | 29.0M shares | 27.8M shares | 26.8M shares |
| Diluted (in shares) | 29.0M shares | 29.3M shares | 26.8M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $116.7M | $119.7M | |
| Marketable investment securities | $182.8M | $173.4M | |
| Accounts receivable, net | $43.4M | $51.2M | |
| Inventory | $10.3M | $8.1M | |
| Prepaid expenses and other current assets | $8.0M | $7.7M | |
| Total current assets | $361.1M | $360.2M | |
| Long-term accounts receivable, net | $1.9M | $918.0K | |
| Property and equipment, net | $97.4M | $51.1M | |
| Operating lease assets | $14.8M | $11.6M | |
| Goodwill and other intangible assets, net | $99.6M | $106.2M | |
| Other assets long-term | $3.8M | $1.2M | |
| Total assets | $578.6M | $531.2M | |
| Accounts payable | $18.7M | $6.9M | |
| Accrued compensation | $38.3M | $32.6M | |
| Contingent consideration | $1.0M | $0 | |
| Operating lease liabilities | $1.3M | $1.7M | |
| Current portion of long-term debt | $417.0K | $278.0K | |
| Other accrued and current liabilities | $8.9M | $8.0M | |
| Total current liabilities | $68.7M | $49.4M | |
| Long-term debt | $9.6M | $9.7M | |
| Noncurrent portion of contingent consideration | $1.5M | $0 | |
| Noncurrent operating lease liabilities | $25.2M | $14.3M | |
| Noncurrent finance lease liabilities | $314.0K | $311.0K | |
| Deferred tax liability | $2.3M | $1.6M | |
| Total liabilities | $107.7M | $75.4M | |
| Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value per share; 200,000,000 authorized as of December 31, 2025 and 2024; 29,686,314 and 28,483,195 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $30.0K | $28.0K | |
| Additional paid-in capital | $694.9M | $655.7M | |
| Accumulated deficit | -$224.3M | -$200.1M | |
| Accumulated other comprehensive income | $267.0K | $230.0K | |
| Total stockholders equity | $470.9M | $455.8M | $391.3M |
| Total liabilities and stockholders equity | $578.6M | $531.2M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 29.7M shares | 28.5M shares | |
| Common stock, shares outstanding (in shares) | 29.7M shares | 28.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$24.2M | $18.2M | -$57.5M |
| Depreciation and amortization | $40.8M | $16.0M | $12.3M |
| Stock-based compensation expense | $45.9M | $50.3M | $51.2M |
| Net gains on equity securities | -$1.5M | -$555.0K | $0 |
| Deferred income taxes | -$6.2M | $1.4M | -$223.0K |
| Accretion of discounts on marketable investment securities | -$4.2M | -$6.7M | -$5.5M |
| Other | $153.0K | $268.0K | $635.0K |
| Accounts receivable | $6.9M | -$12.6M | -$14.9M |
| Prepaid expenses and other current assets | -$544.0K | -$1.1M | -$435.0K |
| Inventory | -$2.1M | -$193.0K | -$4.0M |
| Operating lease assets | $1.4M | $1.3M | -$258.0K |
| Other assets | -$366.0K | $262.0K | -$330.0K |
| Accounts payable | $3.1M | -$4.4M | $5.7M |
| Operating lease liabilities | -$1.3M | -$1.3M | $852.0K |
| Accrued compensation | $5.7M | $3.6M | $4.6M |
| Other accrued and current liabilities | $870.0K | $320.0K | $2.1M |
| Net cash provided by (used in) operating activities | $64.3M | $64.9M | -$5.6M |
| Purchases of marketable investment securities | -$188.7M | -$205.7M | -$189.1M |
| Proceeds from maturities of marketable investment securities | $189.2M | $183.9M | $186.5M |
| Proceeds from sale of equity securities | $1.5M | $0 | $0 |
| Purchases of debt securities classified as held-to-maturity | -$5.6M | $0 | $0 |
| Asset acquisition, net of cash and cash equivalents acquired | -$18.7M | $0 | $0 |
| Issuance of loan receivable | -$2.1M | $0 | $0 |
| Purchases of property and equipment | -$36.0M | -$28.3M | -$13.6M |
| Proceeds from sale of property and equipment | $45.0K | $18.0K | $13.0K |
| Net cash used in investing activities | -$60.4M | -$50.1M | -$16.2M |
| Proceeds from exercise of common stock options | $2.2M | $2.0M | $269.0K |
| Payment of employees taxes on vested restricted stock units | -$11.7M | -$8.8M | -$5.1M |
| Proceeds from contributions to the employee stock purchase plan | $2.4M | $3.0M | $2.7M |
| Repayment of principal portion of finance lease liabilities | -$115.0K | -$97.0K | -$142.0K |
| Proceeds from lease incentives received | $190.0K | $0 | $0 |
| Proceeds from issuance of term debt | $0 | $10.0M | $0 |
| Net cash (used in) provided by financing activities | -$7.0M | $6.1M | -$2.3M |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | -$3.0M | $20.9M | -$24.1M |
| Interest paid, net of amounts capitalized | $59.0K | $434.0K | $11.0K |
| Income taxes, net | $1.6M | $2.5M | $198.0K |
| Accrued purchases of property and equipment | $11.3M | $2.2M | $1.2M |
| Property and equipment acquired with tenant improvement allowance | $7.2M | $1.4M | $1.3M |
| Operating lease assets obtained in exchange for lease obligations | $4.7M | $607.0K | $1.5M |
| Decrease in operating lease assets with corresponding change in lease liabilities | -$104.0K | -$7.0K | $0 |
| Finance lease assets obtained in exchange for lease obligations | $119.0K | $218.0K | $0 |
Recent filings
- Oct 14, 20264
- Oct 13, 2026144
- Oct 7, 20264
- Oct 5, 20264
- Oct 5, 2026144
- Oct 1, 20264
- Oct 1, 2026144
- Sep 23, 20264
- Sep 16, 20264
- Sep 15, 20264
- Sep 14, 2026144
- Sep 11, 2026144
- Sep 3, 20264
- Sep 2, 20264
- Sep 1, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10